Cargando…

Analysis and verification of N(6)-methyladenosine-modified genes as novel biomarkers for clear cell renal cell carcinoma

N(6)-methyladenosine (m(6)A) has been involved in diverse biological processes in cancer, but its function and clinical value in clear cell renal cell carcinoma (ccRCC) remain largely unknown. In this study, we found that 1453 m(6)A-modified differentially expressed genes (DEGs) of ccRCC were mainly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhenyu, Peng, Bo, Pan, Yongbo, Gu, Yinmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810125/ https://www.ncbi.nlm.nih.gov/pubmed/34699322 http://dx.doi.org/10.1080/21655979.2021.1995574

Ejemplares similares

Epitranscriptic regulation of HRAS by N(6)-methyladenosine drives tumor progression
por: Pan, Yongbo, et al.
Publicado: (2023)

N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma
por: Huang, Zhilong, et al.
Publicado: (2022)

DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma
por: Zhu, Yumeng, et al.
Publicado: (2022)

Succinylation Regulators Promote Clear Cell Renal Cell Carcinoma by Immune Regulation and RNA N6-Methyladenosine Methylation
por: Lu, Wenqing, et al.
Publicado: (2021)

RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Li, Huihuang, et al.
Publicado: (2021)

Identification and Verification of Biomarker in Clear Cell Renal Cell Carcinoma via Bioinformatics and Neural Network Model
por: Liu, Bin, et al.
Publicado: (2020)

N(6)-methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma
por: Zheng, Zongtai, et al.
Publicado: (2020)

Prognostic Characteristics and Immune Effects of N(6)-Methyladenosine and 5-Methylcytosine-Related Regulatory Factors in Clear Cell Renal Cell Carcinoma
por: Li, Lei, et al.
Publicado: (2022)

N(6)-methyladenosine (m(6)A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis
por: Yuan, Bao, et al.
Publicado: (2023)

BTG2 suppresses renal cell carcinoma progression through N6-methyladenosine
por: Qi, Fuming, et al.
Publicado: (2022)

Dysregulation and implications of N6-methyladenosine modification in renal cell carcinoma
por: Wu, Yaohai, et al.
Publicado: (2023)

Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N(6)-Methyladenosine RNA Methylation Regulators
por: Zhang, Yan, et al.
Publicado: (2021)

N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma
por: Ma, Tianming, et al.
Publicado: (2021)

METTL14-mediated N(6)-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma
por: Liu, Zhuonan, et al.
Publicado: (2022)

Construction and Characterization of n6-Methyladenosine-Related lncRNA Prognostic Signature and Immune Cell Infiltration in Kidney Renal Clear Cell Carcinoma
por: Chen, Zerong, et al.
Publicado: (2022)

The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer
por: Luo, Lin, et al.
Publicado: (2022)

The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma
por: Deng, Wen, et al.
Publicado: (2021)

N6‐methyladenosine‐modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis‐regulated Hippo pathway
por: Miao, Daojia, et al.
Publicado: (2023)

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC
por: Cheng, Wenli, et al.
Publicado: (2022)

N6‐methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO‐PGC‐1α signalling axis
por: Zhuang, Changshui, et al.
Publicado: (2019)

Integrated analysis on the N6‐methyladenosine‐related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma
por: Qiu, Yuqin, et al.
Publicado: (2021)

N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Guo, Tao, et al.
Publicado: (2021)

Fatty acid metabolism-related genes as a novel module biomarker for kidney renal clear cell carcinoma: Bioinformatics modeling with experimental verification
por: Jia, Zongming, et al.
Publicado: (2023)

circRNA N6-methyladenosine methylation in preeclampsia and the potential role of N6-methyladenosine-modified circPAPPA2 in trophoblast invasion
por: Zhang, Yonggang, et al.
Publicado: (2021)

The Role of N(6)-Methyladenosine Modified Circular RNA in Pathophysiological Processes
por: Tang, Mei, et al.
Publicado: (2021)

Analysis of N6-methyladenosine-modified mRNAs in diabetic cataract
por: Cai, Lei, et al.
Publicado: (2023)

Prognostic value of sirtuin family members and experimental verification identify SIRT5 as diagnostic biomarkers in clear cell renal cell carcinoma
por: Peng, Lu-Shan, et al.
Publicado: (2023)

Function of N6-Methyladenosine Modification in Tumors
por: Zhang, Nan, et al.
Publicado: (2021)

Influence of N6-methyladenosine (m6A) modification on cell phenotype in Alzheimer’s disease
por: Ni, Pengyun, et al.
Publicado: (2023)

Identification of genes modified by N6-methyladenosine in patients with colorectal cancer recurrence
por: Zhu, Qianru, et al.
Publicado: (2022)

Novel insight of N(6)-methyladenosine modified subtypes in abdominal aortic aneurysm
por: Wang, Kangjie, et al.
Publicado: (2022)

Insights into N6-methyladenosine and programmed cell death in cancer
por: Liu, Li, et al.
Publicado: (2022)

N(6)-Methyladenosine and Viral Infection
por: Dang, Wei, et al.
Publicado: (2019)

N6-Methyladenosine RNA Methylation in Cardiovascular Diseases
por: Liu, Chi, et al.
Publicado: (2022)

Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma
por: Wang, Bin, et al.
Publicado: (2022)

Identification and Verification of Immune Subtype-Related lncRNAs in Clear Cell Renal Cell Carcinoma
por: Wang, Zhifeng, et al.
Publicado: (2022)

N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4
por: Li, Zihan, et al.
Publicado: (2020)

Corrigendum to “Function of N6-Methyladenosine Modification in Tumors”
por: Zhang, Nan, et al.
Publicado: (2023)

N6-Methyladenosine-Related lncRNAs Are Anticipated Biomarkers for Sarcoma Patients
por: Zhang, Xiaohe, et al.
Publicado: (2022)

Biomarkers Associated with Immune Checkpoint, N6-Methyladenosine, and Ferroptosis in Patients with Restenosis
por: Tong, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bcp9q8kv5l9mlrs716ddrp6e1l